Following the establishment and characterization of our novel anti-TROP2 mAb described in the current study, we will investigate different treatment modalities, including ADC, RIT, PIT, and CAR-T-cell therapy, to explore TrMab-29-mediated antitumor activities in TROP2-expressing cancers. The gene discussed is TACSTD2; the disease is cancer.